Skip to main content

Table 6 Adverse events (N = 70)

From: RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

 

Any grade

% (n)

G1% (n)

G2% (n)

G3% (n)

G4% (n)

Diarrhea

21.4 (15)

17.1 (12)

4.3 (3)

Nausea

74.3 (52)

35.7 (25)

34.3 (24)

4.3 (3)

Vomit

35.7 (25)

24.3 (17)

8.6 (6)

2.9 (2)

Fatigue

75.7 (53)

40 (28)

34.4 (24)

1.4 (1)

Constipation

7.1 (5)

5.7 (4)

1.4 (1)

Leukopenia

20 (14)

14.3 (10)

4.3 (3)

1.4 (1)

Neutropenia

20 (14)

5.7 (4)

8.6 (6)

5.7 (4)

Neuropathy

20 (14)

11.4 (8)

7.1 (5)

1.4 (1)

Appetite loss

8.6 (6)

4.3 (3)

4.3 (3)